Study Finds AstraZeneca Vaccine to Be 79 Percent Efficient Against Symptomatic COVID-19

Study Finds AstraZeneca Vaccine
to Be 79 Percent Efficient Against
Symptomatic COVID-19.
On Monday, results were announced from a late-stage
study on AstraZeneca’s COVID-19 vaccine, AZD1222. .
The phase 3 trial involved
over 32,000 participants.
AstraZeneca’s vaccine
displayed a 79 percent efficacy
at preventing symptomatic
cases of COVID-19. .
Although that efficacy was consistent across all ages
and ethnicities, it was shown to reach 80 percent in
those 65 years of age and older.
The vaccine also showed
100 percent efficacy at
preventing hospitalization
and severe disease
due to COVID-19.
The trial did not find
any safety concerns
related to the vaccine,
such as an increased
risk for blood clots. .
These findings reconfirm previous
results observed in AZD1222 trials
across all adult populations but it’s
exciting to see similar efficacy results
in people over 65 for the first time … , Ann Falsey, Professor of Medicine at the University of
Rochester School of Medicine.
AstraZeneca is reportedly planning to apply for emergency use authorization from the U.S. Food and Drug Administration sometime in early April. .
If approved, it will be the fourth COVID-19
vaccine offered in the United States